Cargando…

Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload

Antibody-drug conjugates (ADCs), designed to selectively deliver cytotoxic agents to antigen-bearing cells, are poised to become an important class of cancer therapeutics. Human epithelial growth factor receptor (HER2) is considered an effective target for cancer treatment, and a HER2-targeting ADC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yanming, Fan, Shiyong, Zhong, Wu, Zhou, Xinbo, Li, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618509/ https://www.ncbi.nlm.nih.gov/pubmed/28841157 http://dx.doi.org/10.3390/ijms18091860

Ejemplares similares

Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
por: Fu, Zhiwen, et al.
Publicado: (2023)

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018)

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
por: Wang, Yanming, et al.
Publicado: (2020)

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
por: Hingorani, Dina V., et al.
Publicado: (2022)

Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility
por: Satomaa, Tero, et al.
Publicado: (2018)

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
por: Liu-Kreyche, Peggy, et al.
Publicado: (2019)

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo
por: Gallery, Melissa, et al.
Publicado: (2018)

Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
por: Krzyscik, Mateusz A., et al.
Publicado: (2021)

Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
por: Abawi, Ariana, et al.
Publicado: (2021)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
por: Cho, Hanhee, et al.
Publicado: (2022)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
por: Damiani, Isabella, et al.
Publicado: (2021)

Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer
por: Cho, In Kyung, et al.
Publicado: (2022)

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors
por: Krzyscik, Mateusz Adam, et al.
Publicado: (2017)

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023)

Synthesis and Biological Evaluation of RGD and isoDGR–Monomethyl Auristatin Conjugates Targeting Integrin α(V)β(3)
por: Raposo Moreira Dias, André, et al.
Publicado: (2019)

Synthesis and Evaluation of a Monomethyl Auristatin E—Integrin α(v)β(6) Binding Peptide–Drug Conjugate for Tumor Targeted Drug Delivery
por: Davis, Ryan A., et al.
Publicado: (2023)

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
por: Świderska, Karolina Weronika, et al.
Publicado: (2018)

Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery
por: Kim, Jihoon, et al.
Publicado: (2021)

Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Park, Min-Ho, et al.
Publicado: (2019)

Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity
por: Sokka, Iris K., et al.
Publicado: (2021)

Antibody–drug conjugates: Recent advances in payloads
por: Wang, Zhijia, et al.
Publicado: (2023)

Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins
por: Zhou, Qun
Publicado: (2023)

Development of applicable thiol-linked antibody–drug conjugates with improved stability and therapeutic index
por: Wang, Yanming, et al.
Publicado: (2022)

Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
por: Fujii, Tomohiro, et al.
Publicado: (2021)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
por: Waight, Andrew B., et al.
Publicado: (2016)

Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy
por: Dorywalska, Magdalena, et al.
Publicado: (2015)

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy
por: Wang, Yanming, et al.
Publicado: (2019)

Antibody-Drug Conjugates Containing Payloads from Marine Origin
por: Cheng-Sánchez, Iván, et al.
Publicado: (2022)

Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021)

Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1
por: Nawrocka, Daria, et al.
Publicado: (2023)

Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates
por: Karpov, Alexei S., et al.
Publicado: (2018)

Payload diversification: a key step in the development of antibody–drug conjugates
por: Conilh, Louise, et al.
Publicado: (2023)

Disulfide re-bridging reagents for single-payload antibody-drug conjugates
por: King, Thomas A., et al.
Publicado: (2023)

Synthesis and characterization of new polyamides derived from alanine and valine derivatives
por: El-Faham, Ayman, et al.
Publicado: (2012)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates
por: Liu, Lianqi, et al.
Publicado: (2021)

Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
por: Adhikari, Ajeeth, et al.
Publicado: (2021)

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
por: Ryan, M C, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bi2v3og5jb2rnii4miduvv0uqh